Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 113 Show results per page	View Search Criteria \| Help With Results

Last Modified: 4/1/1988


1.		Phase II/III Study of IFN-beta-ser/IFN-gamma Followed by DDP/VP-16 in Patients with Inoperable non-Small Cell Lung Cancer (Summary Last Modified 04/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								WCCC-CO-8751 NCI-V87-0225

Last Modified: 12/6/2007 First Published: 9/24/2003


2.		Phase II/III Randomized Study of Immunotherapy Comprising Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Patients With Refractory or Relapsed Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				Under 30				NCI				COG-AHOD0121 NCT00070187, AHOD0121

Last Modified: 9/27/2007 First Published: 9/1/1998


3.		Phase III Randomized Study of Autologous Graft Versus Host Disease in Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				NCI				JHOC-97080106 JHOC-9726, NCI-V98-1453, NCT00003414

Last Modified: 5/22/2008 First Published: 1/1/2001


4.		Phase III Randomized Study of High-Dose Cyclophosphamide, Thiotepa, and Carboplatin and Autologous Bone Marrow or Peripheral Blood Stem Cell Transplantation in Conjunction With Cyclosporine and Interferon Gamma Versus Interleukin-2 as Immunomodulation in Women With High-Risk Stage II or III Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 to physiologic 65				NCI				CPMC-IRB-7608 CPMC-CAMP-014, NCI-G00-1890, NCT00008203


5.		Phase III Comparison of Immuneron vs Depo-Provera in Patients with Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75								BGSM-89285 NCI-V85-0243


6.		Phase III Randomized Trial of Immunotherapy with IFN-alpha vs IFN-gamma vs IFN-alpha/IFN-gamma in Patients with Advanced Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over								BGSM-89186 NCI-V86-0108

Last Modified: 3/1/2001


7.		Phase III Randomized Evaluation of Dosage Schedule and Sequencing of VP-16/CACP Combination Chemotherapy as Induction Therapy and Randomized Study of Gamma IFN for Intensification of CR in Small Cell Lung Cancer (Summary Last Modified 03/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				NCCTG-862051 NCCTG-86-20-51

Last Modified: 5/9/2007


8.		Phase III Randomized Trial of Adjuvant Recombinant Human Interferon-Gamma vs No Adjuvant Therapy Following Complete Surgical Excision in Patients with Stage I/II Melanoma at High Risk for Recurrence

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 to physiologic 70				NCI				SWOG-8642 SWOG-8642

Last Modified: 2/20/2008


9.		Phase III Randomized Trial of Recombinant IFN-G and of 5-FU/CF as Adjuvant Therapy vs No Adjuvant Therapy in Patients with Resectable Adenocarcinoma of the Colon

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				NCCTG-874651 MAYO-874651, MDA-DM-89021, NCCTG-87-46-51

Last Modified: 6/1/1988


10.		Phase III Randomized Study of Adjuvant Treatment with IFN-A vs IFN-G vs No Adjuvant Therapy in Patients with Resected High-Risk Stage I/IIB Malignant Melanoma (Summary Last Modified 06/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				any age								EORTC-18871

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute